Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Metastatic Hormone-Refractory Prostate Cancer
NCT00337077Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2006
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in prostate cancer (PCa), sponsored by National Cancer Institute. Started Nov 2006; status: completed.
02
Drugs
eribulin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00337077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337077.